Key Highlights

  • ConvaTec Group Plc (LSE:CTEC) is in focus after Smith & Nephew's confirmation of Merger approaches revived interest in UK medical technology stocks on 4 November 2026.
  • ConvaTec has said it is on track to deliver its 2026 guidance after a good start to the year.
  • The shares closed at 242.4p on 3 November, well above the levels near 199p seen in May.
  • US reimbursement rules for advanced wound care products remain a key Factor for the sector.

Why ConvaTec Is in Focus Today

ConvaTec Group Plc (LSE:CTEC) is drawing attention on the FTSE 100 as the UK medical technology sector came alive on Wednesday, 4 November 2026. Smith & Nephew shares jumped more than 6% after the company confirmed it had approached Johnson & Johnson about combining with the DePuy Synthes orthopaedics business. Deal activity in one part of a sector often prompts investors to reassess valuations across peers, and ConvaTec, a specialist in wound care, ostomy, continence and infusion devices, is one of the few other MedTech groups in the index.

The wider market also offered support. The FTSE 100 rose 1.8% to 10,829.21 as the US midterm elections, which handed control of both chambers of Congress to the Democrats, boosted risk appetite. Healthcare policy in the United States is a major factor for ConvaTec, which generates a large share of its Revenue there, so political shifts in Washington are closely watched.

Recovery From May Lows

ConvaTec shares have had a volatile year. In May 2026 the stock tumbled about 7% to 199.8p even though the company said it had enjoyed a good start to the year and was on track to deliver its 2026 guidance. It slipped again the following day to around 198.7p as investors worried about growth quality and US reimbursement changes. Since then the shares have recovered substantially and closed at 242.4p on Tuesday, 3 November, a rise of more than 20% from the spring lows. That recovery reflects improved confidence in the company's ability to meet its targets.

The Business

ConvaTec operates across four main franchises. Advanced Wound Care includes dressings and skin substitute products used to treat chronic and acute wounds. Ostomy Care provides products for people living with a stoma. Continence Care, which includes catheters, has been a fast-growing area driven by product innovation and home delivery services in the United States. Infusion Care supplies sets used with insulin pumps and other infusion devices, giving exposure to the growing diabetes technology market.

Management has been focused on improving margins through productivity programmes and on driving growth from new product launches. The group's medium-term ambitions include sustained organic revenue growth and expanding operating margins.

US Reimbursement Backdrop

One of the most important issues for the advanced wound care industry in 2026 has been reimbursement reform in the United States for skin substitute products. Smith & Nephew said earlier this year that these changes could reduce its full-year revenue by close to $40 million. ConvaTec also sells products in this area, so investors follow policy developments closely. The new political balance in Congress could influence healthcare spending debates, although reimbursement decisions largely sit with federal agencies.

Market Context on 4 November

The Smith & Nephew update showed the mixed conditions facing medtech companies, with growth in sports medicine and wound devices offset by weakness in US hips and knees. For ConvaTec, which does not Supply orthopaedic implants, the read-across is largely about valuation and the appetite of larger groups to acquire specialist businesses. Healthcare stocks had lagged other sectors earlier in the week, with heavyweight healthcare names weighing on the index on Monday, so Wednesday's sector rebound was welcome for investors.

Risks to Consider

Risks include changes to US reimbursement, pricing pressure from healthcare systems, supply chain costs, product recalls and competition from larger rivals. Currency movements also affect reported results because most revenue is earned outside the UK. Any slowdown in continence or infusion growth would weigh on sentiment.

What Investors Are Watching Next

Investors will look for further updates on trading and confirmation that 2026 guidance remains on track, with full-year results expected in early 2027. Developments in US reimbursement for wound biologics, progress with new product launches and Margin delivery will be key. Any further merger activity in the medical technology sector, including the outcome of Smith & Nephew's strategic review, could also influence how investors value ConvaTec Group Plc (LSE:CTEC).